p16ARC抗体—艾普蒂 新品

+ +

•  

   

     All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.    

  
  

•  

   

     All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.    

  
  

•  

   

     Western blot analysis of p16 Arc expression in Human fetal brain lysate.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human colon, using p16 ARC Antibody.    

  
  

The p16 antibody targets the p16 protein, a critical tumor suppressor encoded by the *CDKN2A* gene. Discovered in the 1990s, p16 plays a pivotal role in regulating the cell cycle by inhibiting cyclin-dependent kinases (CDK4 and CDK6), thereby preventing Rb protein phosphorylation and halting G1-to-S phase progression. Dysregulation of p16 is strongly linked to carcinogenesis, with loss of expression commonly observed in various cancers due to gene deletion, methylation, or mutation. Conversely, overexpression of p16 is often associated with cellular senescence and aging, as well as human papillomavirus (HPV)-related malignancies, where viral oncoproteins disrupt normal cell cycle control.

The p16 antibody is widely utilized in research and diagnostics to detect p16 expression via immunohistochemistry (IHC), Western blotting, or immunofluorescence. In clinical settings, it serves as a biomarker for HPV-driven cancers, such as cervical and oropharyngeal squamous cell carcinomas, where elevated p16 levels correlate with viral oncogenic activity. Additionally, it aids in distinguishing benign lesions from precancerous or malignant tissues. Commercial p16 antibodies are typically raised against specific epitopes of the human protein, ensuring specificity for targeted applications. Ongoing studies continue to explore its prognostic value and therapeutic potential in cancer biology.